Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055347 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4ETDP1NPSR1SMN1; SMN2 | |
| SCHEMBL3428537 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4ETDP1NPSR1SMN1; SMN2 | |
| SCHEMBL21338969 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4ETDP1NPSR1SMN1; SMN2 | |
| SCHEMBL13173639 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4ETDP1NPSR1SMN1; SMN2 | |
| SCHEMBL16649161 | 0.79 | CYP11B1 (0.46) | ALDH1A1KDM4ETDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL582977 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL4766176 | 0.78 | CYP11B1 (0.42) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1CYP11B1 | |
| SCHEMBL16139574 | 0.78 | CYP11B1 (0.42) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1CYP11B1 | |
| SCHEMBL12382082 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KDM4ETDP1NPSR1CYP11B1 | |
| SCHEMBL13173637 | 0.76 | ALDH1A1 (0.40) | ALDH1A1KDM4ETDP1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | claimed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025045246-A1 | PARP7 INHIBITOR AND USE THEREOF | 重庆华森英诺生物科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| CN-119330972-A | PARP7 inhibitor and application thereof | 重庆华森英诺生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-1746997-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CZCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006060108-A1 | N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| WO-2005115392-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-4990512-A | Insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-02-05 | — | — | US | disclosed |
| EP-0357201-A2 | Pyridyl pyrimidinone derivatives with an insecticidal activity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ALDH1A1 686/4885KDM4E 497/4885TDP1 1568/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | ALDH1A1 1490/4885KDM4E 4296/4885TDP1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.